Conference Abstracts - The 8th International Cancer Congress
Vol. 6, Issue Supplement 2, 2026 · S1-2
Mutational Profile and Genetic Classification of Diffuse Large B-Cell Lymphoma in an Indian Patient Cohort
Anu Kumari, PhD,Anupriya Kaur, DM,Priyanka Srivastava, PhD,Gaurav Prakash, DM,Rajender Kumar, MD,Sreejesh Sreedharanunni, DM,Amanjit Bal, DM,Pankaj Malhotra, DM
Submission received: 2026-08-12 / Accepted: 2026-08-30 / Published: 2026-09-24
Abstract
Background
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphoma. It is currently classified into 3 subtypes based on cell of origin (COO): GCB, non-GCB and Unclassified type. The above classification aids in the identification & diagnosis of DLBCL but has little clinical impact, especially for the post-R-CHOP therapy relapse/refractory disease. Clinical research in lymphomagenesis is thus aimed at identifying genetic markers that can explain significant alterations in the disease course and ultimately inform druggable targets, if any.
Methods
Fifty newly diagnosed, treatment-naïve patients with DLBCL were prospectively enrolled. A customized 15 gene targeted panel was sequenced on Ion Torrent GeneStudio S5 platform. Somatic variants were classified according to ClinGen-CGC-VICC guidelines. Genetic subtypes were assigned using the LymphGen 2.0 algorithm
Results
50 consecutive patients with DLBCL were enrolled. Median age of the cohort was 51 years (18-76y) with a male-to-female ratio of 1.7/1. The TP53 harbored the highest number of oncogenic/likely oncogenic variants followed by TNFAIP3, EZH2, NOTCH1, CD79B, MYC and STAT6, B2M and CDKN2A (Figure 1). The non-GCB subgroup had higher number of O/LO variations as compared to GCB group. Among the various genetic subtypes, the EZB type was the largest (53.3%) in our cohort (Figure 2). An equal number of these 24 cases were GCB and non-GCB in origin. In the composite genetic subtypes or non-core EZB types (n=14), the non-GCB types were higher in numbers than the GCB types.
Conclusion
Clinical research in lymphomagenesis is moving towards identifying genetic subgroups. This will allow collection of necessary data to determine which groups are significant, which treatments may be indicated, and will provide better insight to clinicians and patients on specific disease course. We plan to perform more comprehensive genomic profiling and have applied for grants to do tumour whole exome sequencing in future research cohorts.